Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Received ANDA Approval for Metoprolol Succinate ER Tablets
Details : Generic version of Metoprolol Succinate ER Tablets have been approved, these are catecholamines inhibitor indicated for the treatment of hypertension in order to lower blood pressure.
Product Name : Toprol-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2012
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2012
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Eris Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln
Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 13, 2024
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Eris Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of speci...
Product Name : Toprol-XL
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 04, 2022
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2018
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2013
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2013
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : National Heart, Lung, and Blood Institute | GSK | AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2013
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : National Heart, Lung, and Blood Institute | GSK | AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
